Home Nation News Govt Likely to Float Global Tender for HPV Vaccine in April; Merck, Serum Institute May Participate

Govt Likely to Float Global Tender for HPV Vaccine in April; Merck, Serum Institute May Participate

0
Govt Likely to Float Global Tender for HPV Vaccine in April; Merck, Serum Institute May Participate

Last Updated: January 29, 2023, 13:55 IST

India, at present, is fully dependent on foreign manufacturers for HPV vaccines. (Representational image: Reuters)

India, at current, is totally depending on international producers for HPV vaccines. (Representational picture: Reuters)

Serum Institute’s made-in-India HPV vaccine “CERVAVAC” was launched by Union Home Minister Amit Shah on January 24, in presence of the Pune-based agency’s CEO Adar Poonawalla and Prakash Kumar Singh, its Director-Government and Regulatory Affairs

The Health Ministry intends to roll out HPV vaccine towards cervical most cancers in the nationwide immunisation programme for women aged 9 to 14 years in June for which a worldwide tender is probably going to be floated in April, official sources have stated.

Serum Institute’s made-in-India HPV vaccine “CERVAVAC” was launched by Union Home Minister Amit Shah on January 24, in presence of the Pune-based firm’s CEO Adar Poonawalla and Prakash Kumar Singh, its Director-Government and Regulatory Affairs.

“The ministry is likely to float in April a global tender for 16.02 crore doses of HPV vaccine, which will be supplied by 2026. Apart from domestic manufacturer Serum Institute of India, global vaccine manufacturer Merck is also likely to participate in the tender,” an official supply stated.

In July final 12 months, India’s drug regulator granted market authorization to Serum Institute of India’s indigenously developed HPV vaccine. It has additionally been cleared by authorities advisory panel National Technical Advisory Group on Immunisation (NTAGI) for use in the general public well being programme.

Prakash Kumar Singh, on the sidelines of a South Asia meet on HPV final month, had stated that the worth of CERVAVAC will probably be reasonably priced in contrast to the worldwide HPV vaccine accessible in India.

India, at current, is totally depending on international producers for HPV vaccines. Globally, three international corporations manufacture HPV vaccines out of which two promote their doses in India.

Each dose of the vaccine accessible in the market prices greater than Rs 4,000, sources stated.

In September 2022, Poonawalla had stated that every dose of its “CERVAVAC” vaccine would cost Rs 200 to Rs 400.

India, which is home to about 16 per cent of the world’s women, accounts for about a quarter of all cervical cancer incidences and nearly a third of global cervical cancer deaths.

Indian women face a 1.6 per cent lifetime cumulative risk of developing cervical cancer and a one per cent cumulative death risk from cervical cancer, according to officials.

Recent estimates state that every year almost 80,000 women develop cervical cancer and 35,000 die in India due to it.  On what prevented India from introducing the HPV vaccine till now, NTAGI chief Dr N K Arora had said that the vaccine supply has been a limiting factor globally.

Fortunately, over the last five years, the global supply of the HPV vaccine has been improving gradually.

India has taken a lead in this direction. Serum Institute of India, one of the major Indian vaccine manufacturers, with support from the Centre’s Department of Biotechnology has developed four valent HPV vaccine.  The vaccine has received regulatory approval and cleared by NTAGI for use in public health programmes.

“We are given to understand that three other Indian vaccine manufacturers are also in various stages of developing the HPV vaccine,” an official had stated.

Read all of the Latest India News right here

(This story has not been edited by News18 employees and is revealed from a syndicated information company feed)

Source hyperlink

LEAVE A REPLY

Please enter your comment!
Please enter your name here